Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials
- PMID: 34839015
- DOI: 10.1016/j.annonc.2021.11.008
Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials
Conflict of interest statement
Disclosure AP has served in a consultant/advisory role for AstraZeneca, Agilent/Dako, Boehringer Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Merck Sharp & Dohme, Janssen, Novartis, Pfizer and Roche Genentech, outside the submitted work. FdM has served in a consultant/advisory role for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, Novartis, Roche Genentech, Takeda and Pfizer, outside the submitted work. IA has declared no conflicts of interest.
Comment on
-
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆.Ann Oncol. 2022 Feb;33(2):169-180. doi: 10.1016/j.annonc.2021.11.002. Epub 2021 Nov 18. Ann Oncol. 2022. PMID: 34800678 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
